BR9813256A - Composto, composição farmacêutica, e, processos para tratar de um paciente com uma doença neurodegenerativa, para prevenir o inìcio de uma doença neurodegenerativa em um paciente, para tratar de um paciente com uma doença autoimune, para prevenir o inìcio de uma doença autoimune em um paciente, para tratar de um paciente com uma doença inflamatória e para prevenir o inìcio de uma doença inflamatória em um paciente - Google Patents

Composto, composição farmacêutica, e, processos para tratar de um paciente com uma doença neurodegenerativa, para prevenir o inìcio de uma doença neurodegenerativa em um paciente, para tratar de um paciente com uma doença autoimune, para prevenir o inìcio de uma doença autoimune em um paciente, para tratar de um paciente com uma doença inflamatória e para prevenir o inìcio de uma doença inflamatória em um paciente

Info

Publication number
BR9813256A
BR9813256A BR9813256-3A BR9813256A BR9813256A BR 9813256 A BR9813256 A BR 9813256A BR 9813256 A BR9813256 A BR 9813256A BR 9813256 A BR9813256 A BR 9813256A
Authority
BR
Brazil
Prior art keywords
patient
disease
onset
prevent
treating
Prior art date
Application number
BR9813256-3A
Other languages
English (en)
Inventor
Judith A Kelleher
Julian Levell
Kirk R Maples
Alina Dykman
Yong-Kang Zhang
Allan L Wilcox
Original Assignee
Centaur Phamaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centaur Phamaceuticals Inc filed Critical Centaur Phamaceuticals Inc
Publication of BR9813256A publication Critical patent/BR9813256A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C291/00—Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00
    • C07C291/02—Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00 containing nitrogen-oxide bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C291/00—Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00
    • C07C291/02—Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00 containing nitrogen-oxide bonds
    • C07C291/04—Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00 containing nitrogen-oxide bonds containing amino-oxide bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/18—Systems containing only non-condensed rings with a ring being at least seven-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)

Abstract

"COMPOSTO, COMPOSIçãO FARMACêUTICA, E, PROCESSOS PARA TRATAR DE UM PACIENTE COM UMA DOENçA NEURODEGENERATIVA, PARA PREVENIR O INìCIO DE UMA DOENçA NEURODEGENERATIVA EM UM PACIENTE, PARA TRATAR DE UM PACIENTE COM UMA DOENçA AUTOIMUNE, PARA PREVENIR O INìCIO DE UMA DOENçA AUTOIMUNE EM UM PACIENTE, PARA TRATAR DE UM PACIENTE COM UMA DOENçA INFLAMATóRIA E PARA PREVENIR O INìCIO DE UMA DOENçA INFLAMATóRIA EM UM PACIENTE" São apresentados novos compostos de <244>-aril-N-alquilnitrona e composições farmacêuticas contendo tais compostos. As composições apresentadas são úteis como agentes terapêuticos para impedir e/ou tratar de condições neurodegenerativas, autoimunes e inflamatórias em mamíferos e como reagentes analíticos para detectar radicais livres.
BR9813256-3A 1997-10-17 1998-10-16 Composto, composição farmacêutica, e, processos para tratar de um paciente com uma doença neurodegenerativa, para prevenir o inìcio de uma doença neurodegenerativa em um paciente, para tratar de um paciente com uma doença autoimune, para prevenir o inìcio de uma doença autoimune em um paciente, para tratar de um paciente com uma doença inflamatória e para prevenir o inìcio de uma doença inflamatória em um paciente BR9813256A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US6232497P 1997-10-17 1997-10-17
US6373697P 1997-10-29 1997-10-29
US9047598P 1998-06-24 1998-06-24
PCT/US1998/021624 WO1999020601A1 (en) 1997-10-17 1998-10-16 α-ARYL-N-ALKYLNITRONES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME

Publications (1)

Publication Number Publication Date
BR9813256A true BR9813256A (pt) 2000-08-29

Family

ID=27370256

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9813256-3A BR9813256A (pt) 1997-10-17 1998-10-16 Composto, composição farmacêutica, e, processos para tratar de um paciente com uma doença neurodegenerativa, para prevenir o inìcio de uma doença neurodegenerativa em um paciente, para tratar de um paciente com uma doença autoimune, para prevenir o inìcio de uma doença autoimune em um paciente, para tratar de um paciente com uma doença inflamatória e para prevenir o inìcio de uma doença inflamatória em um paciente

Country Status (24)

Country Link
US (5) US6046232A (pt)
EP (1) EP1025079B1 (pt)
JP (1) JP2001520217A (pt)
KR (1) KR20010024520A (pt)
CN (1) CN1281432A (pt)
AR (1) AR015969A1 (pt)
AT (1) ATE288419T1 (pt)
AU (1) AU1083399A (pt)
BR (1) BR9813256A (pt)
CA (1) CA2305798A1 (pt)
DE (1) DE69828895T2 (pt)
ES (1) ES2235374T3 (pt)
HU (1) HUP0004398A3 (pt)
ID (1) ID25543A (pt)
IL (1) IL135646A0 (pt)
MA (1) MA26553A1 (pt)
NO (1) NO20001914L (pt)
NZ (1) NZ503910A (pt)
PL (1) PL340003A1 (pt)
SK (1) SK5512000A3 (pt)
TN (1) TNSN98187A1 (pt)
TR (1) TR200001023T2 (pt)
TW (1) TWI226882B (pt)
WO (1) WO1999020601A1 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046232A (en) 1997-10-17 2000-04-04 Centaur Pharmaceuticals, Inc. α-aryl-N-alkylnitrones and pharmaceutical compositions containing the same
US6194465B1 (en) 1998-05-19 2001-02-27 Centaur Pharmaceuticals, Inc. Benzamide therapeutics for the treatment of inflammatory bowel disease
WO1999059576A1 (en) * 1998-05-19 1999-11-25 Centaur Pharmaceuticals, Inc. Aryl nitrone therapeutics for the treatment of inflammatory bowel disease
US6083989A (en) * 1999-05-18 2000-07-04 Centaur Pharmaceuticals, Inc. Aryl nitrone therapeutics for the treatment of inflammatory bowel disease
DE69917643T2 (de) 1998-07-17 2004-10-07 Renovis Inc Alpha-(2-hydroxyphenyl)nitrone, diese enthaltenden pharmazeutische zubereitungen sowie deren verwendung zur behandlung von entzündungen
US6730700B2 (en) 1998-12-02 2004-05-04 Renovis, Inc. 3,4,5,-trisubstituted aryl nitrone compounds and pharmaceutical compositions containing the same
UA66401C2 (en) 1998-12-02 2004-05-17 Sentor Pharmaceuticals Inc 3,4,5-trisubstituted aryl nitrone compounds and pharmaceutical composition containing the same
BR9904931A (pt) * 1999-10-18 2001-06-12 Sergio Teixeira Ferreira Inibição de amiloidoses
WO2001035951A2 (en) * 1999-11-18 2001-05-25 Centaur Pharmaceuticals, Inc. Aryl nitrone therapeutics and methods for treating inflammatory bowel disease
US6444702B1 (en) 2000-02-22 2002-09-03 Neuromolecular, Inc. Aminoadamantane derivatives as therapeutic agents
US6664297B1 (en) 2000-10-18 2003-12-16 Universidade Federal Do Rio De Janeiro Methods for inhibition and dissolution of amyloidoses by administration of compositions comprising 2,4-dinitrophenol
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
WO2002065993A2 (en) 2001-01-08 2002-08-29 Centaur Pharmaceuticals, Inc. Use of aryl nitrone compounds in methods for treating neuropathic pain
KR20040016849A (ko) * 2001-04-02 2004-02-25 파노라마 리서치, 인크. 치료제로 사용되는 항산화제 니트로옥사이드 및 니트론류
US7115666B2 (en) * 2002-10-15 2006-10-03 Renovis, Inc. Nitrone compounds, pharmaceutical compositions containing the same and methods for treating inflammation and neuropathic pain
US6762322B1 (en) 2002-12-20 2004-07-13 Goodyear Tire & Rubber Company Preparation of nitrone derivatives
WO2004103233A1 (en) * 2003-05-15 2004-12-02 Cutanix Corporation Compositions containing a combination of a pharmaceutical agent or a cosmetic agent and an oxy group-bearing aromatic aldehyde
US20050059638A1 (en) * 2003-08-04 2005-03-17 Kelly Michael G. Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders
US20050182060A1 (en) * 2004-02-13 2005-08-18 Kelly Michael G. 2-Substituted and 4-substituted aryl nitrone compounds
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
CA2604052C (en) 2005-04-06 2014-07-08 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of cns-related conditions
FR2898602B1 (fr) * 2006-03-17 2012-06-22 Ts Pharma Nouveaux derives amphiphiles de l'alpha-c-phenyl-n-tert butyl nitrone
CN101468970B (zh) * 2008-04-25 2011-05-11 暨南大学 一种硝酮类化合物及其制备方法和在制药中的应用
MX365650B (es) 2009-12-02 2019-06-10 Adamas Pharmaceuticals Inc Composiciones de amantadina y metodos para su uso.
CN102311396B (zh) * 2010-07-05 2015-01-07 暨南大学 一种吡嗪类衍生物和其制备方法及在制药中的应用
EP2661264B1 (en) 2011-01-07 2018-12-05 Allergan, Inc. Melanin modification compositions and methods of use
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
CN107488090B (zh) * 2017-06-22 2020-06-02 东北师范大学 一种n-环丙基硝酮化合物的高效催化不对称制备方法
CN107522635B (zh) * 2017-06-22 2020-02-14 东北师范大学 一类n-环丙基硝酮衍生物及其制备方法
CN109438288B (zh) * 2018-10-22 2021-05-07 河南中医药大学 一种n-硝酮取代芳香酰胺衍生物及其制备方法
CN112479936A (zh) * 2020-12-16 2021-03-12 怀化学院 一种苯偶酰衍生物硝酮的制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3666754A (en) * 1965-11-06 1972-05-30 Dainippon Pharmaceutical Co 2-(5-nitrofuryl) nitrone derivatives
US3834073A (en) * 1971-05-03 1974-09-10 Scm Corp Phenyl nitrone derivatives useful as seed protectants
US3849934A (en) * 1971-05-03 1974-11-26 Scm Corp Alpha-aryl-n-lower alkyl nitrone-containing compositions useful as anti-fungal agents
US3903049A (en) * 1974-01-30 1975-09-02 Goodyear Tire & Rubber Oxidation resistant sulfur curable rubbery polymers
US3917700A (en) * 1974-01-30 1975-11-04 Goodyear Tire & Rubber Nitrone compounds
IT1133010B (it) * 1980-05-15 1986-07-09 Sigma Tau Ind Farmaceuti Metodo terapuetico per il trattamento del diabete mellito a insorgenza giovanile e composizione farmaceutica per tale metodo
GB2137619A (en) * 1983-03-30 1984-10-10 Gerald Scott Nitrone compounds and stabilised rubber compositions containing them
US5723502A (en) * 1985-07-18 1998-03-03 Proctor; Peter H. Topical spin trap composition and method
US5352442A (en) * 1985-07-18 1994-10-04 Proctor Peter H Topical tempo
ATE110954T1 (de) * 1988-01-29 1994-09-15 Peter H Proctor Haarwachstumanregung mit nitroxyd und anderen radikalen.
DE69012138T2 (de) * 1989-10-17 1995-04-06 Oklahoma Medical Research Foundation, Oklahoma, Okla. Verfahren und zubereitungen zur hemmung von mit oxidativer schädigung assoziierten krankheiten.
ATE209908T1 (de) * 1991-06-18 2001-12-15 Oklahoma Med Res Found RADIKALFÄNGER (ßSPIN TRAPSß) ZUR BEHANDLUNG VON MIT OXIDATION VON LIPIDEN UND PROTEINEN VERBUNDENEN ERKRANKUNGEN
US5292746A (en) * 1991-09-12 1994-03-08 Merrell Dow Pharmaceuticals Inc. Cyclic nitrones, pharmaceutical compositions thereof and their use in treating shock
US5455272A (en) * 1993-10-22 1995-10-03 Oklahoma Medical Research Foundation Spin trap nitronyl hindered phenols
US5488145A (en) * 1993-12-23 1996-01-30 Oklahoma Medical Research Foundation 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps
CA2235765C (en) * 1995-11-17 2006-04-04 David A. Becker Azulenyl nitrone spin trapping agents, methods of making and using same
TW429241B (en) * 1996-09-26 2001-04-11 Sumitomo Pharma Nitrone derivatives
US6046232A (en) * 1997-10-17 2000-04-04 Centaur Pharmaceuticals, Inc. α-aryl-N-alkylnitrones and pharmaceutical compositions containing the same

Also Published As

Publication number Publication date
JP2001520217A (ja) 2001-10-30
MA26553A1 (fr) 2004-12-20
TNSN98187A1 (fr) 2005-03-15
ES2235374T3 (es) 2005-07-01
WO1999020601A1 (en) 1999-04-29
US6046232A (en) 2000-04-04
US20050124691A1 (en) 2005-06-09
AU1083399A (en) 1999-05-10
US6441032B1 (en) 2002-08-27
EP1025079A1 (en) 2000-08-09
EP1025079B1 (en) 2005-02-02
ID25543A (id) 2000-10-12
IL135646A0 (en) 2001-05-20
DE69828895T2 (de) 2006-01-19
KR20010024520A (ko) 2001-03-26
NZ503910A (en) 2002-09-27
TR200001023T2 (tr) 2000-11-21
SK5512000A3 (en) 2001-01-18
DE69828895D1 (de) 2005-03-10
CN1281432A (zh) 2001-01-24
ATE288419T1 (de) 2005-02-15
PL340003A1 (en) 2001-01-15
CA2305798A1 (en) 1999-04-29
US20030087957A1 (en) 2003-05-08
TWI226882B (en) 2005-01-21
HUP0004398A2 (hu) 2001-05-28
NO20001914D0 (no) 2000-04-12
AR015969A1 (es) 2001-05-30
US6433008B1 (en) 2002-08-13
HUP0004398A3 (en) 2001-11-28
NO20001914L (no) 2000-06-02

Similar Documents

Publication Publication Date Title
BR9813256A (pt) Composto, composição farmacêutica, e, processos para tratar de um paciente com uma doença neurodegenerativa, para prevenir o inìcio de uma doença neurodegenerativa em um paciente, para tratar de um paciente com uma doença autoimune, para prevenir o inìcio de uma doença autoimune em um paciente, para tratar de um paciente com uma doença inflamatória e para prevenir o inìcio de uma doença inflamatória em um paciente
ATE199552T1 (de) Substituierte benzolaktamverbindungen als substanz-p-antagonisten
ATE263563T1 (de) Mittel gegen juckreiz
BR0008922A (pt) Compostos úteis como agentes antiinflamatórios
BR9711805A (pt) Compostos e métodos para providenciar preparações farmacologicamente ativas e uso dos mesmos
BR9911488A (pt) Composto, uso do mesmo, composição farmacêutica, e, processos para tratamento ou de profilaxia de doenças inflamatórias, e para a preparação de um composto
IS4073A (is) Nýtt fjölvirknislyf gegn aukningu mótstöðu
GT199700079A (es) Derivados triciclos sustituidos con fenilamino
BRPI0007487B8 (pt) difenil-uréias substituídas com w-carbóxi-arilas como inibidores de raf cinase
PT896533E (pt) Pentafluorobenzenosulfonamidas e analogos
PT842934E (pt) Agonistas de 5-ht1f
PT627221E (pt) Substancias antagonistas p para o tratamento de emese
BR9608789A (pt) Compostos de tetralina com atividade de mdr
PT100850A (pt) Composicoes farmaceuticas contendo uma mistura sinergica de um agente uricosurico, em especial,de probenecid, com um agente antagonista de aminoacidos excitantes, em especial,um derivado de quinoxalina substituido e sua utilizacao no tratamento de doencas neurodegenerativas
BRPI0411319A (pt) compostos terapeuticamente ativos e sua utilização
DE69805672D1 (de) Verwendung von Rifaximin als Medikament zur Behandlung von durch Cryptosporidiose verursachten Diarrhoeen
BR9708114A (pt) Análogos xantona para o tratamento de doenças infecciosas.
BR9808157A (pt) Processo de inibição do desenvolvimento de células tumorais e de tumor e composição farmacêutica
ES2133324T3 (es) Compuestos de dibenzoxazepina sustituidos, composiciones farmaceuticas y metodos de uso.
TR199902334T2 (xx) Psikotik bozukluklar�n tedavisi veya profilaksisi i�in mirtazapin ve antipsikotik ajanlar�n yeni terap�tik kombinasyonlar�.
DE69729183T2 (de) Als entzündungshemmende mittel nützliche dihydrobenzofurane und verwandte verbindungen
DE69842133D1 (de) Zusammensetzungen und Kits zur Erhöhung der Abgabe von therapeutischen Mitteln an Zellen
EA200100607A1 (ru) 3,4,5-тризамещенные арилнитроны и содержащие их фармацевтические композиции
BR0008302A (pt) Uso de um derivado de benzaldeìdo, derivado de benzaldeìdo, composição farmacêutica, e, processo para a fabricação da mesma
ATE381327T1 (de) Cethylmyristat und cetylpalmitat zurbehandlung von ekzemen und/oder psoriasis

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved
B25A Requested transfer of rights approved

Free format text: RENOVIS, INC. (US)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE PATENTE DE ACORDO COM ART. 8O DA LPI.